Nventa's HspE7 vaccine plus adjuvant more potent against HPV

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Nventa Biopharmaceuticals Corp. said preclinical data showed that HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases, had greater potency and activation of the immune response when combined with Poly-ICLC or the TLR-9 agonist CpG.

Responses were measured by ELISpot analysis or observations made in vivo using antigen-positive TC-1 tumors.

The San Diego-based pharmaceutical company is filing patent applications around the use of HspE7 plus adjuvant and expects to advance HspE7 into human clinical trials using Ploy-ICLC.

Nventa presented the HspE7 data at the 23rd International Papillomavirus Conference in Prague.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.